The Korean Journal of Gastroenterology (대한소화기학회지)

The Korean Society of Gastroenterology (대한소화기학회)
권호 표지

Two Cases of Metronidazole-induced Encephalopathy

메트로니다졸에 의해 유발된 뇌증 2예

Kim, Kook-Hyun;Choi, Jae-Won;Lee, Ji-Yun;Kim, Tae-Dong;Paek, Jong-Hae;Lee, Eun-Ju;Oh, Hyun-A;Kim, Jun-Hwan;Jang, Byeong-Ik;Kim, Tae-Nyeun;Chung, Moon-Kwan;Lee, Heon-Ju;Byun, Woo-Mok
김국현;최재원;이지은;김태동;백종해;이은주;오현아;김준환;장병익;김태년;정문관;이헌주;변우목

  • Published : 20050300
⟨ Previous Next ⟩

Abstract

Metronidazole is a 5-nitroimidazole compound known as an antimicrobial agent widely used for the treatment of protozoal infection, anaerobic infection, Helicobacter pylori infection and hepatic encephalopathy. It may produce a number of neurologic side effects including peripheral neuropathy, seizure, encephalopathy, ataxic gait and dysarthritic speech. There have been ten or more reports of metronidazole-induced encephalopathy in the literatures including a few reports of brain imaging changes by magnetic resonance images (MRI). However, none of the case of metronidazole-induced encephalopathy in patients with hepatic encephalopathy has been reported yet. Recently, we experienced two cases of metronidazole-induced encephalopathy in patients with liver cirrhosis caused by chronic hepatitis B, which were diagnosed by brain MRI and MR spectroscopy. In this report, we present 2 cases of metronidazole-induced encephalopathy with MR imaging and MR spectroscopic changes including followup imaging performed after the discontinuation of the metronidazole with a review of the literatures.

Keywords

References

  1. Lamp KC, Freeman CD, Klutman NE, Lacy MK. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet 1999;36:353-373 https://doi.org/10.2165/00003088-199936050-00004
  2. Loft S, Sonne J, Dossing M, Andreasen PB. Metronidazole pharmacokinetics in patients with hepatic encephalopathy. Scand J Gastroenterol 1987;22:117-123 https://doi.org/10.3109/00365528708991867
  3. Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ. Central nervous system toxicity associated with metronidazole therapy. Ann Intern Med 1980;93:59-60 https://doi.org/10.7326/0003-4819-93-1-59
  4. Frytak S, Moertel CH, Childs DS. Neurologic toxicity associated with high-dose metronidazole therapy. Ann Intern Med 1978;88:361-362 https://doi.org/10.7326/0003-4819-88-3-361
  5. Bradley WG, Karlsson IJ, Rassol CG. Metronidazole neuropathy. Br Med J 1977;2:610-611 https://doi.org/10.1136/bmj.2.6087.610
  6. Seok JI, Yi H, Song YM, Lee WY. Metronidazole-induced encephalopathy and inferior olivary hypertrophy: lesion analysis with diffusion-weighted imaging and apparent diffusion coefficient maps. Arch Neurol 2003;60:1796-1800 https://doi.org/10.1001/archneur.60.12.1796
  7. Kim DW, Park JM, Yoon BW, Baek MJ, Kim JE, Kim S. Metronidazole-induced encephalopathy. J Neurol Sci 2004; 224:107-111 https://doi.org/10.1016/j.jns.2004.06.012
  8. Kim DS, Jung JW, Kim JY, Kim JH, Kim EG, Kim SE. Reversible MRI findings in metronidazole-induced cerebellar dysfunction. J Korean Neurol Assoc 1999;17:904-907
  9. Rao DN, Mason RP. Generation of nitro radical anions of some 5-nitrofurans, 2- and 5-nitroimidazoles by norepinephrine, dopamine, and serotonin. A possible mechanism for neurotoxicity caused by nitroheterocyclic drugs. J Biol Chem 1987;262:11731-11736
  10. Ahmed A, Loes DJ, Bressler EL. Reversible magnetic resonance imaging findings in metronidazole-induced encephalopathy. Neurology 1995;45:588-589 https://doi.org/10.1212/WNL.45.3.588
  11. Heaney CJ, Campeau NG, Lindell EP. MR imaging and diffusion- weighted imaging changes in metronidazole (Flagyl)- induced cerebellar toxicity. Am J Neuroradiol 2003;24:1615- 1617
  12. Cecil KM, Halsted MJ, Schapiro M, Dinopoulos A, Jones BV. Reversible MR imaging and MR spectroscopy abnormalities in association with metronidazole therapy. J Comput Assist Tomogr 2002;26:948-951 https://doi.org/10.1097/00004728-200211000-00016
  13. Horlen CK, Seifert CF, Malouf CS. Toxic metronidazoleinduced MRI changes. Ann Pharmacother 2000;34:1273-1275 https://doi.org/10.1345/aph.10028
  14. Woodruff BK, Wijdicks EF, Marshall WF. Reversible metronidazole- induced lesions of the cerebellar dentate nuclei. N Engl J Med 2002;346:68-69 https://doi.org/10.1056/NEJM200201033460117
  15. Ito H, Maruyama M, Ogura N, et al. Reversible cerebellar lesions induced by metronidazole therapy for Helicobacter pylori. J Neuroimaging 2004;14:369-371 https://doi.org/10.1177/1051228404267597
  16. Thomas MA, Huda A, Guze B, et al. Cerebral 1H MR spectroscopy and neuropsychologic status of patients with hepatic encephalopathy. AJR Am J Roentgenol 1998;171:1123-1130 https://doi.org/10.2214/ajr.171.4.9763008
  17. Seo DW, Lee JH, Lee YS, et al. Proton magnetic resonance spectroscopic findings in cirrhotic patients with hepatic encephalopathy: the significance of decreased myoinositol/creatine ratio. Korean J Gastroenterol 1998;31:498-511
  18. von Rogulja P, Kovac W, Schmid H. Metronidazole encephalopathy in rats. Acta Neuropathol (Berl) 1973;25:36-45 https://doi.org/10.1007/BF00686856
  19. Chang KH, Cha SH, Han MH, Park SH, Nah DL, Hong JH. Marchiafava-Bignami disease: serial changes in corpus callosum on MRI. Neuroradiology 1992;34:480-482 https://doi.org/10.1007/BF00598954
  20. Kawarabuki K, Sakakibara T, Hirai M, Yoshioka Y, Yamamoto Y, Yamaki T. Marchiafava-Bignami disease: magnetic resonance imaging findings in corpus callosum and subcortical white matter. Eur J Radiol 2003;48:175-177 https://doi.org/10.1016/S0720-048X(02)00349-2